A medicine giving the "prospect of a cure" for Hepatitis C is one of four accepted for routine use by NHS Scotland.
The Scottish Medicines Consortium (SMC) approved the use of Elbasvir-grazoprevir, known as Zepatier, on Monday, saying it is "a combination of two medicines that inhibit the replication of the Hepatitis C virus and offers the prospect of a cure for Hepatitis C infection".
The consortium also approved Pembrolizumab, known as Keytruda, which can give late-stage non-small cell lung cancer patients two more months to live.
Deferasirox (Exjade) was accepted for treatment of an excess of iron in some patients with a rare blood disorder, and the Butec buprenorphine skin patch was approved to ease chronic pain not associated with cancer in people aged 65 and over.
The consortium rejected two treatments for patients with the rare white blood cell cancer multiple myeloma due to uncertainties about the evidence on benefits versus costs.
SMC chairman Professor Jonathan Fox said: "I am pleased that we were able to accept four new medicines for routine use in NHS Scotland.
"Unfortunately the committee was unable to accept two medicines for the treatment of multiple myeloma."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article